Literature DB >> 22138765

Selection and characterization of tenascin C targeting peptide.

Mee Young Kim1, Ok Ran Kim, Yong Seok Choi, Heuiran Lee, Keerang Park, Choon-Taek Lee, Keon Wook Kang, Sunjoo Jeong.   

Abstract

Since tenascin C is a factor expressed highly in the tumor-associated matrix, it would be a desirable first step for targeting the tumor-specific microenvironment. In fact, a high level of tenascin C expression has been reported in most solid tumors, including lung cancer, colon cancer and glioblastoma. Therefore, the targeted binding of tenascin C in tumor stroma would inhibit tumor metastasis by modulating cancer cell growth and migration. We isolated a peptide that bound to tenascin C by phage display peptide library selection, and the selected peptide specifically recognized tenascin C protein in xenograft mouse tissue. We also observed exclusive staining of tenascin C by the selected peptide in tumor patient tissues. Moreover, the peptide reduced tenascin C-induced cell rounding and migration. We propose that the tenascin C targeting peptide may be useful as a specific anti-cancer diagnostic and therapeutic tool for most human solid tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138765      PMCID: PMC3887746          DOI: 10.1007/s10059-012-2214-4

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  26 in total

1.  Tumor cell-targeting by phage-displayed peptides.

Authors:  Ulla B Rasmussen; Valerie Schreiber; Huguette Schultz; Fabienne Mischler; Klaus Schughart
Journal:  Cancer Gene Ther       Date:  2002-07       Impact factor: 5.987

2.  Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids.

Authors:  M Grifman; M Trepel; P Speece; L B Gilbert; W Arap; R Pasqualini; M D Weitzman
Journal:  Mol Ther       Date:  2001-06       Impact factor: 11.454

3.  Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.

Authors:  Matthew Adams; J Louise Jones; Rosemary A Walker; J Howard Pringle; Stephen C Bell
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation.

Authors:  A Juuti; S Nordling; J Louhimo; J Lundin; C Haglund
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

5.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Authors:  David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Ilkcan Cokgor; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy N Rich; Lorna V Regalado; John H Sampson; Timothy D Shafman; Carol J Wikstrand; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  The brain microenvironment and cancer metastasis.

Authors:  Isaiah J Fidler; Krishnakumar Balasubramanian; Qingtang Lin; Seung Wook Kim; Sun-Jin Kim
Journal:  Mol Cells       Date:  2010-08-19       Impact factor: 5.034

Review 7.  Potential oncogenic action of tenascin-C in tumorigenesis.

Authors:  Gertraud Orend
Journal:  Int J Biochem Cell Biol       Date:  2005-01-18       Impact factor: 5.085

Review 8.  Tenascins.

Authors:  Ruth Chiquet-Ehrismann
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

Review 9.  Connective tissues: signalling by tenascins.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

10.  Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.

Authors:  Stephen J White; Stuart A Nicklin; Hildegard Büning; M Julia Brosnan; Kristen Leike; Emmanuel D Papadakis; Michael Hallek; Andrew H Baker
Journal:  Circulation       Date:  2004-01-19       Impact factor: 29.690

View more
  15 in total

Review 1.  Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis.

Authors:  Christopher Schultz
Journal:  Br J Pharmacol       Date:  2018-11-22       Impact factor: 8.739

Review 2.  Homing Peptides for Cancer Therapy.

Authors:  Prakash Lingasamy; Tambet Teesalu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease.

Authors:  Guo-Hong Cui; Hai-Dong Guo; Han Li; Yu Zhai; Zhang-Bin Gong; Jing Wu; Jian-Sheng Liu; You-Rong Dong; Shuang-Xing Hou; Jian-Ren Liu
Journal:  Immun Ageing       Date:  2019-05-13       Impact factor: 6.400

Review 4.  Phage display screening of therapeutic peptide for cancer targeting and therapy.

Authors:  Phei Er Saw; Er-Wei Song
Journal:  Protein Cell       Date:  2019-05-28       Impact factor: 14.870

5.  Immune-mediated ECM depletion improves tumour perfusion and payload delivery.

Authors:  Yen Ling Yeow; Venkata Ramana Kotamraju; Xiao Wang; Meenu Chopra; Nasibah Azme; Jiansha Wu; Tobias D Schoep; Derek S Delaney; Kirk Feindel; Ji Li; Kelsey M Kennedy; Wes M Allen; Brendan F Kennedy; Irma Larma; David D Sampson; Lisa M Mahakian; Brett Z Fite; Hua Zhang; Tomas Friman; Aman P Mann; Farah A Aziz; M Priyanthi Kumarasinghe; Mikael Johansson; Hooi C Ee; George Yeoh; Lingjun Mou; Katherine W Ferrara; Hector Billiran; Ruth Ganss; Erkki Ruoslahti; Juliana Hamzah
Journal:  EMBO Mol Med       Date:  2019-11-11       Impact factor: 12.137

6.  Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors.

Authors:  Yukun Huang; Yu Chen; Songlei Zhou; Liang Chen; Jiahao Wang; Yuanyuan Pei; Minjun Xu; Jingxian Feng; Tianze Jiang; Kaifan Liang; Shanshan Liu; Qingxiang Song; Gan Jiang; Xiao Gu; Qian Zhang; Xiaoling Gao; Jun Chen
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

Review 7.  Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.

Authors:  Wenpan Li; Nicholas Little; Jonghan Park; Cole Alexander Foster; Jiawei Chen; Jianqin Lu
Journal:  Mol Pharm       Date:  2021-07-14       Impact factor: 4.939

Review 8.  Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche.

Authors:  Alejandro Luarte; Luis Federico Bátiz; Ursula Wyneken; Carlos Lafourcade
Journal:  Stem Cells Int       Date:  2016-04-19       Impact factor: 5.443

Review 9.  Targeting ECM Disrupts Cancer Progression.

Authors:  Freja A Venning; Lena Wullkopf; Janine T Erler
Journal:  Front Oncol       Date:  2015-10-20       Impact factor: 6.244

Review 10.  Molecular Determinants of Malignant Brain Cancers: From Intracellular Alterations to Invasion Mediated by Extracellular Vesicles.

Authors:  Gabriella Schiera; Carlo Maria Di Liegro; Italia Di Liegro
Journal:  Int J Mol Sci       Date:  2017-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.